Medtronic plc (ETR:2M6)
Germany · Delayed Price · Currency is EUR | Market Cap | 112.95B +9.8% |
| Revenue (ttm) | 32.64B +9.8% |
| Net Income | 4.55B +12.3% |
| EPS | 3.66 +12.1% |
| Shares Out | n/a |
| PE Ratio | 25.05 |
| Forward PE | 16.19 |
| Dividend | 2.48 (2.71%) |
| Ex-Dividend Date | Sep 25, 2026 |
| Volume | 1,726 |
| Open | 91.84 |
| Previous Close | 91.00 |
| Day's Range | 91.22 - 92.80 |
| 52-Week Range | 62.86 - 94.50 |
| Beta | 0.57 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 24, 2026 |
About Medtronic
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and rem... [Read more]
Financial Performance
In fiscal year 2026, Medtronic's revenue was $36.36 billion, an increase of 8.43% compared to the previous year's $33.54 billion. Earnings were $4.80 billion, an increase of 2.98%.
Financial numbers in USD Financial StatementsNews
Medtronic price target raised to $120 from $110 at BofA
BofA raised the firm’s price target on Medtronic (MDT) to $120 from $110 and keeps a Buy rating on the shares. Medical technology investor sentiment is “slightly less negative” than…
Medtronic to announce financial results for its second quarter of fiscal year 2027
GALWAY, Ireland, Nov. 4, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results on Tuesday, November 24, 2026, ...
TCT26: Medtronic Symplicity blood pressure procedure shows significant blood pressure drops in SPYRAL AFFIRM real-world study
Nearly nine out of 10 patients experienced a clinical benefit at six months Medtronic receives FDA approval for U.S. labeling update to Symplicity blood pressure procedure, expanding clinical evidence...
Orchestra BioMed Announces Virtue SAB Presentation at TCT 2026
Presentation will highlight Virtue SAB's fundamentally different approach of infusing a large liquid volume of proprietary extended-release SirolimusEFR™ directly into and throughout the vessel wall. ...
Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB
NEW HOPE, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pati...
Medtronic reports results from Sphere-9 catheter, PulseSelect PFA System
Medtronic (MDT) announced positive real-world registry results for the Affera Mapping and Ablation System with the Sphere-9 Catheter and the PulseSelect Pulsed Field Ablation System. The global regist...
Medtronic announces positive results from real-world registries for the Sphere-9™ catheter and PulseSelect™ PFA System at APHRS 2026
Global APEX and REAL PULSE Registry analyses report strong safety and procedural outcomes across atrial and ventricular arrhythmias Medtronic continues to strengthen its position in cardiac ablation, ...
Medtronic EVP, Pres MedSurg and Americas Marinaro Michael sells $1M of shares
In a regulatory filing, Medtronic (MDT) disclosed that EVP, Pres MedSurg and Americas, Marinaro Michael, sold 10,420 shares at $96.00 on October 15, for a total transaction size of about…
Medtronic Chairman and CEO sells $4.75M of company shares
In a regulatory filing, Medtronic (MDT) disclosed that Chairman and CEO Martha Geoffrey sold 50,000 shares at $95.00 on October 15, for a total transaction size of $4.75M. Published first…
Medtronic Named to TIME Best Inventions of 2026 List for Stealth AXiS™ surgical system and Corsano™* multi-parameter wearable
Annual list recognizes inventions making the world better and smarter GALWAY, Ireland, Oct. 15, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announce...
Medtronic Completes Separation of MiniMed Group, Inc.
GALWAY, Ireland, Oct. 15, 2026 /PRNewswire/ -- Medtronic plc (Medtronic; NYSE: MDT) today announced the completion of its separation of MiniMed Group, Inc. (MiniMed; Nasdaq: MMED). "I'm incredibly pro...
MiniMed Completes Separation from Medtronic
NORTHRIDGE, Calif., Oct. 15, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED) today announced the completion of its separation from Medtronic plc ("Medtronic"; NYSE: MDT), marking its first day as a fully ...
Medtronic Announces Final Results of MiniMed Group, Inc. Exchange Offer
GALWAY, Ireland, Oct. 14, 2026 /PRNewswire/ -- Medtronic plc (Medtronic; NYSE: MDT) today announced the final results of its previously announced offer to exchange shares of common stock of MiniMed Gr...
Medtronic says MiniMed exchange offer oversubscribed
Medtronic (MDT) announced that, based on preliminary results, its previously announced offer to exchange shares of common stock of MiniMed Group (MMED) for outstanding Medtronic ordinary shares was ov...
Medtronic Announces Preliminary Results of MiniMed Group, Inc. Exchange Offer
GALWAY, Ireland, Oct. 12, 2026 /PRNewswire/ -- Medtronic plc (Medtronic; NYSE: MDT) today announced that, based on preliminary results, its previously announced offer to exchange shares of common stoc...
Medtronic price target lowered to $99 from $100 at BTIG
BTIG lowered the firm’s price target on Medtronic (MDT) to $99 from $100 and keeps a Buy rating on the shares as part of a broader research note previewing Q3…
Medtronic Announces Final Exchange Ratio of 4.5939 in Split-Off of MiniMed Group, Inc.
GALWAY, Ireland, Oct. 7, 2026 /PRNewswire/ -- Medtronic plc (Medtronic; NYSE: MDT) today announced the final exchange ratio for its previously announced offer to exchange outstanding Medtronic ordinar...
Medtronic initiated with an Equal Weight at Barclays
Barclays initiated coverage of Medtronic (MDT) with an Equal Weight rating and $95 price target The firm rolled out coverage of the medical suppliers and devices group with a Positive…
Why Medtronic's $4 Billion MiniMed Exchange Offer Is Losing Its Allure
The tax-free exchange offer allows Medtronic investors to swap their shares for MiniMed shares held by Medtronic in what Wall Street calls a split-off.
Medtronic’s Altaviva and Symplicity Spyral Systems granted Category I CPT Codes
Medtronic (MDT) announced that the American Medical Association approved new Category I Current Procedural Terminology – CPT – codes for two of its technologies: Altaviva implantable tibial neuromodul...
Medtronic Receives Category I CPT® Code Approvals for Altaviva™ and Symplicity Spyral™ Systems
Coding approvals reflect growing clinical evidence and physician adoption of Medtronic solutions addressing urge urinary incontinence and hypertension GALWAY, Ireland, Oct. 1, 2026 /PRNewswire/ -- Me...
Medtronic announces regulatory milestones for newest cardiac mapping and ablation software
FDA clearance and CE Mark for latest Affera™ Prism-2 Mapping Software expand cardiac mapping capabilities CE Mark for PulseSelect ProxBox™ Adapter with Proximity Indicator software adds real-time tiss...
Medtronic announces FDA clearance for LigaSure™ RAS Maryland instrument on the Hugo™ RAS system
Trusted vessel-sealing technology used in more than 45 million procedures worldwide is now cleared for robotic-assisted surgery in the U.S. GALWAY, Ireland, Sept. 16, 2026 /PRNewswire/ -- Medtronic (N...
Medtronic Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Strong acute procedure volumes, AI-driven innovation, and robust growth in key franchises are fueling sustained top-line expansion. Strategic investments in robotics and portfolio optimization, along with operational improvements, support margin expansion and a positive outlook, with further details expected at the upcoming Investor Day.